Saturday , December 16 2017
Home / Resources / Articles / Clinical Trial Shows GlycoMark Test is Key In Diabetes Management

Clinical Trial Shows GlycoMark Test is Key In Diabetes Management

New studies show GlycoMark may be a more effective monitor than A1c of exenatide, sitagliptin, pramlintide and prandaial insulin thereapies in certain diabetic populations.

GlycoMark, Inc. announced today results from the ongoing DURABLE clinical trial showing that the GlycoMark blood test is a better reflection of glucose, particularly after-meal glucose levels, than the gold standard hemoglobin A1C test in moderately controlled patients with diabetes.  These findings were reported by Kathleen Dungan, MD, of Ohio State University (Columbus, OH) and investigators from Eli Lilly (Indianapolis, IN) at the American Diabetes Association’s 68th Annual Scientific Sessions (ADA) in San Francisco.

This is the largest clinical study to evaluate the clinical utility of GlycoMark to reflect after-meal glucose levels with 2,094 patients enrolled from 11 countries.  The DURABLE trial (Assessing the Durability of Basal vs. Lispro Mix 75/25 Insulin Efficacy) confirms results from a smaller population study completed by John Buse, MD (University of North Carolina), Steven Wittlin, MD (University of Rochester), and Kathleen Dungan, MD, published in the medical journal Diabetes Care in June 2006.

In the study, the 1,5-Anhydroglucitol blood test (GlycoMark) correlated more strongly than hemoglobin A1C with all self-monitored plasma glucose (SMPG) parameters, particularly after-meal glucose levels, in moderately controlled patients with A1C levels less than 8.0%.  Dr. Dungan concluded, "The data support the use of 1,5-anhydroglucitol, in conjunction with A1C, in moderately controlled patients with type 2 diabetes."

"This large clinical study validates the important role of the GlycoMark test to effectively monitor patients with diabetes," said Eric Button, President of GlycoMark, Inc.  "Although patients may appear to be adequately controlled by A1C results, it may not readily reveal elevated postprandial spikes which are associated with dangerous cardiovascular complications.  GlycoMark can detect ‘hidden’ glucose spikes, allowing physicians to target these spikes with specific treatments."

Linda Stine, Pharmacist told me that our patients want to see immediate results and the use of the GlycoMark test might improve compliance and convince patients to stay on their medications.

================================

Advertisement
Do you, or someone that you know, need guidance and support to deal with the challenges of weight, food and diabetes?
From May 21 – July 2, Fit4D coaches will be presenting a six week class focused on WEIGHT MANAGEMENT & DIABETES

Dial in from anywhere in the USA and Canada using your phone and Internet connection for this virtual class!
 

Class registration is available at: http://www.fit4d.com/ or by calling 866-411-0254.  Mention Diabetes in Control and receive 10% off of the May Class or a 1:1 Personalized Coaching Membership!